Temporal trends in heart failure mortality in an integrated healthcare delivery system, California, and the US, 2001–2017
verfasst von:
Matthew T. Mefford, Zimin Zhuang, Zhi Liang, Wansu Chen, Sandra Y. Koyama, Maria T. Taitano, Heather L. Watson, Ming-Sum Lee, Stephen Sidney, Kristi Reynolds
In recent years, decreases in mortality rates attributable to cardiovascular diseases have slowed but mortality attributable to heart failure (HF) has increased.
Methods
Between 2001–2017, trends in age-adjusted mortality with HF as an underlying cause for Kaiser Permanente Southern California (KPSC) members were derived through linkage with state death files and compared with trends among California residents and the US. Average annual percent change (AAPC) and 95% confidence intervals (CI) were calculated using Joinpoint regression. Analyses were repeated examining HF as a contributing cause of death.
Results
In KPSC, the age-adjusted HF mortality rates were comparable to California but lower than the US, increasing from 23.9 per 100,000 person-years (PY) in 2001 to 44.7 per 100,000 PY in 2017, representing an AAPC of 1.3% (95% CI 0.0%, 2.6%). HF mortality also increased in California from 33.9 to 46.5 per 100,000 PY (AAPC 1.5%, 95% CI 0.3%, 2.7%), while remaining unchanged in the US at 57.9 per 100,000 PY in 2001 and 2017 (AAPC 0.0%, 95% CI − 0.5%, 0.5%). Trends among KPSC members ≥ 65 years old were similar to the overall population, while trends among members 45–64 years old were flat between 2001–2017. Small changes in mortality with HF as a contributing cause were observed in KPSC members between 2001 and 2017, which differed from California and the US.
Conclusion
Lower rates of HF mortality were observed in KPSC compared to the US. Given the aging of the US population and increasing prevalence of HF, it will be important to examine individual and care-related factors driving susceptibility to HF mortality.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Heart failure (HF) is a major public health problem that is associated with high hospital readmission rates, mortality, and health care expenditures [1]. Despite treatment advances, mortality remains high with approximately 50% of HF patients dying within 5 years of their diagnosis [1]. Overall, 1 in 8 deaths list HF as a contributing cause [2]. While all-cause mortality and the mortality attributable to cardiovascular disease (CVD) have declined over the past decades, declines in rates of CVD mortality began slowing in 2011 [3‐9]. Mortality attributable to HF, in contrast, began increasing around this time [4, 10]. Explanations for the increase in HF mortality may include the aging population, the increasing prevalence of comorbidities, and the growing prevalence of HF with preserved ejection fraction, which lacks specific evidence-based treatments [11‐14]. Examining temporal trends in HF mortality is important as this may reflect changes in individual, or institutional factors, and can inform healthcare policy and practice [15]. Integrated healthcare delivery systems are associated with better adherence to evidence-based care guidelines, survival rates, and reduced racial disparities [16‐18]. Kaiser Permanente Southern California (KPSC) serves approximately 4.6 million enrollees and largely reflects the diverse population of southern California, making it ideal to study mortality trends [19]. Therefore the purpose of the current study was to examine secular trends in HF mortality among adults ≥ 45 years old in KPSC, California, and the US, from 2001 to 2017.
Methods
Study population
KPSC is an integrated healthcare delivery system that serves approximately 20% of the Southern California population. At enrollment into the health plan, date of birth and sex were collected administratively. Race/ethnicity was based on a combination of administrative and patient self-report as previously described [20]. Health plan enrollees 45–110 years old with enrollment between 2001 and 2017 were included in the current analysis. For each member, the total number of days enrolled was considered the at-risk time for each year. At-risk time for each year began on the date of KPSC enrollment or January 1, whichever occurred later, and ended at disenrollment from the KPSC health plan, date of death, or December 31, whichever occurred first. Gaps in enrollment ≤ 45 days, including those that spanned 2 consecutive years, were bridged (i.e., continuous enrollment was assumed). Members with missing information on date of birth or sex labeled as “other” or “unknown” were excluded. Enrollees with race/ethnicity other than non-Hispanic white, non-Hispanic black, Hispanic, and Asian/Pacific Islander, or who had missing information on race were included in analyses not specific to race/ethnicity. The study protocol was approved by the KPSC institutional review board.
Anzeige
Mortality
HF as an underlying and, separately, contributing cause of death was identified among eligible adults. The underlying cause of death is defined as the disease or injury that initiates the chain of morbid events leading directly to death [21]. Contributing causes of death are defined as all significant diseases, conditions, or injuries that contributed to death but which did not result in the underlying cause of death. KPSC death records were derived by identifying deaths that occurred at KPSC-owned facilities (i.e., patient electronic health records), outside facilities that submitted claims to KPSC, or deaths reported to the health plan. Additionally, death records were supplemented by linking members with decedents in the California Death Statistical Master Files, the California Comprehensive Death File, the State Multiple Cause of Death File, and the Social Security Administration (SSA) Death Master Files. Linkage of the death files to members in KPSC has been described previously [15]. Causes of death were determined by International Classification of Diseases, Clinical Modification, 10th Revision (ICD-10-CM) codes in the California State death files. US and California mortality rates between 2001 and 2017 for adults ≥ 45 years old were derived from the Center for Disease Control’s (CDC) Wide-Ranging Online Data for Epidemiologic Research CDC WONDER dataset, which includes underlying and contributing causes of death from death certificates filed in the 50 states and the District of Columbia [2, 22]. Underlying cause of death from HF was identified with ICD-10 code I50.x. HF as a contributing cause of death was defined as mortality with an underlying cardiovascular cause (ICD-10 codes I00-I78) with HF listed as a contributing cause [23].
Statistical analysis
Age, sex, and race/ethnicity were described overall and for each year from 2001 to 2017. Overall, sex-stratified, and race-stratified age-adjusted mortality rates per 100,000 person-years (PY) were calculated using the direct method with the 2000 US Census population as the standard population. US Census counts are reported in 5-year age intervals [24].
Average annual percentage changes (AAPC) in mortality rates and 95% confidence intervals (CI) were estimated using the Joinpoint Regression Program, Version 4.5.0.1 (Statistical Research and Applications Branch, National Cancer Institute) [25]. To compare AAPCs in KPSC with California and the US, we calculated a z-statistic by dividing the difference in the two AAPCs (KPSC vs California; or KPSC vs US) and the standard error (SE) of the difference (i.e., square root [SE12 + SE22], where SE1 and SE2 are the standard errors of the two individual estimates). The analysis was performed on a log scale, and conducted overall and by age and sex groups, separately. We additionally calculated HF mortality rates within race/ethnicity groups (white, black, Hispanic, Asian/Pacific Islander [API]) over the same study period.
Given evidence of increasing rates of HF mortality since 2011 [10], we also examined trends from 2001–2011 and 2011–2017, separately. Using best-fit Joinpoint models for the entire study period (2001–2017) period-specific AAPCs for 2001–2011 and 2011–2017 were calculated [25]. Best-fit models were selected by permutation testing that identified the optimal number of knots [26]. We repeated the above analyses to examine mortality with HF listed as a contributing cause of death overall and by sex. All tests were two-sided and p < 0.05 was considered statistically significant.
Anzeige
Results
Within KPSC, members ≥ 45 years old increased from 0.95 million in 2001 to approximately 1.78 million in 2017. (Table 1) From 2001 to 2017, the proportion of adults 45–64 years old decreased (69.0% to 63.8%) while the proportion of adults ≥ 65 years old increased (31.0% to 36.2%). The proportions of white and black adults decreased (55.3% to 43.4% and 12.1% to 9.7%, respectively) while the proportions of Hispanic and API adults increased (23.8% to 34.8% and 8.9% to 12.2%, respectively).
Table 1
Demographic characteristics of Kaiser Permanente Southern California adult enrollees ≥ 45 years of age, 2001–2017
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
Enrollees, n
945,676
996,689
1,030,657
1,059,319
1,104,743
1,157,917
1,201,172
1,235,241
1,276,507
1,330,215
1,389,925
1,448,424
1,493,217
1,569,391
1,666,634
1,726,153
1,783,391
Deaths, %
1.3
1.3
1.3
1.3
1.3
1.2
1.2
1.1
1.1
1.1
1.11
1.1
1.2
1.1
1.2
1.2
1.2
Age, years, %
45–54
41.0
40.6
40.0
39.5
39.3
39.4
39.4
39.1
38.2
37.2
36.4
35.3
34.3
33.8
33.7
33.2
32.6
55–64
28.0
28.7
29.2
29.6
29.9
30.4
30.8
31.1
31.5
31.9
32.0
31.5
31.3
31.2
31.3
31.2
31.2
65–74
18.7
18.4
18.4
18.4
18.1
17.7
17.4
17.4
17.7
18.1
18.7
19.9
20.9
21.3
21.4
21.9
22.2
75–84
9.8
9.8
9.8
9.8
9.8
9.6
9.5
9.3
9.4
9.5
9.5
9.7
10.0
10.0
9.9
10.0
10.2
85 +
2.5
2.6
2.7
2.7
2.8
2.9
3.0
3.1
3.2
3.3
3.4
3.5
3.6
3.6
3.7
3.8
3.8
Male, %
46.5
46.4
46.4
46.4
46.5
46.5
46.6
46.6
46.6
46.6
46.6
46.7
46.7
46.7
46.8
46.8
46.7
Race/Ethnicity*, %
API
8.9
9.1
9.3
9.5
9.7
9.9
10.1
10.4
10.6
10.8
11.0
11.1
11.2
11.4
11.6
11.8
12.2
Black
12.1
11.8
11.7
11.7
11.5
11.3
11.2
11.1
11.0
10.8
10.7
10.5
10.4
10.2
10.0
9.8
9.7
Hispanic
23.8
24.7
25.3
26.0
27.0
28.1
28.9
29.6
29.9
30.0
30.3
30.8
31.4
32.5
33.4
34.2
34.8
NH White
55.3
54.3
53.7
52.9
51.8
50.8
49.8
49.0
48.6
48.4
48.1
47.7
47.0
45.9
45.0
44.1
43.4
API Asian/Pacific Islander; NH White Non-Hispanic White
*Among members with known race/ethnicity
HF as an underlying cause of death
Between 2001 and 2017, KPSC rates of mortality with HF as an underlying cause were similar to California but lower compared to the US. In KPSC, the age-adjusted mortality rate with HF as the underlying cause increased from 23.9 per 100,000 PY in 2001 to 44.7 per 100,000 PY in 2017, representing an AAPC of 1.3% (95% CI 0.0%, 2.6%). (Fig. 1 and Table 2) During the same time period, HF mortality rates also increased in California from 33.9 to 46.5 per 100,000 PY (AAPC 1.5%, 95% CI 0.3%, 2.7%), while remaining unchanged in the US at 57.9 per 100,000 PY in 2001 and 2017 (AAPC 0.0%, 95% CI − 0.5%, 0.5%). From 2001–2017, HF mortality trends were not different comparing KPSC to California and the US (all p-values > 0.05 [data not shown]). In KPSC, the AAPCs for women and men were 4.1% (95% CI − 3.7%, 12.6%) and 1.3% (95% CI 0.1%, 2.5%), respectively, between 2001 and 2017. Sex-specific trends from 2001 to 2017 were not statistically different from those in California and the US. In KPSC, HF mortality increased at the same rate from 2001 to 2011 and 2011 to 2017. In contrast, HF mortality rates remained flat in California and in the US from 2001 to 2011 while significantly increasing from 2011 to 2017.
Fig. 1
Mortality with heart failure as an underlying cause in KPSC, California, and the US, 2001–2017
Table 2
Mortality with HF as the underlying cause in KPSC, California, and the United States, 2001–2017
Year
KPSC
California
United States
Male
Female
Overall
Male
Female
Overall
Male
Female
Overall
2001
34.4
16.4
23.9
37.2
31.7
33.9
60.9
55.3
57.9
2002
46.4
27.1
35.0
37.3
32.8
34.7
60.1
54.0
56.8
2003
44.9
32.3
37.3
42.5
35.7
38.5
60.5
53.7
56.6
2004
35.9
31.8
33.5
40.2
35.5
37.5
59.0
52.8
55.5
2005
42.1
35.5
38.3
41.2
37.5
39.2
59.1
53.5
56.0
2006
41.9
38.1
39.7
43.7
40.7
42.1
59.5
53.1
55.9
2007
37.6
32.5
35.0
39.0
33.9
36.0
55.2
48.2
51.2
2008
37.2
35.5
36.5
40.3
35.1
37.4
53.9
47.3
50.3
2009
47.7
33.5
39.4
41.4
33.7
36.9
53.7
45.2
48.8
2010
41.9
28.2
33.8
40.3
34.0
36.6
54.4
45.2
49.1
2011
47.4
36.6
40.8
43.0
35.8
38.8
53.0
44.4
48.1
2012
43.6
28.8
34.8
42.7
32.5
36.7
54.2
44.2
48.5
2013
40.9
32.3
36.0
42.7
34.2
37.7
57.4
46.4
51.1
2014
37.6
24.9
30.1
42.4
35.1
38.3
59.2
47.8
52.7
2015
43.0
35.1
38.5
48.5
38.0
42.5
63.9
51.0
56.5
2016
52.2
36.0
42.7
52.0
39.6
45.0
65.4
51.8
57.7
2017
50.8
39.6
44.7
53.5
41.0
46.5
66.0
51.9
57.9
AAPC (95% CI)
Overall
1.3*
(0.1, 2.5)
4.1 (−3.7, 12.6)
1.3*
(0.0, 2.6)
2.2*
(1.2, 3.1)
1.6 (−0.1, 3.4)
1.5*
(0.3, 2.7)
0.5*
(0.1, 1.0)
−0.2
(−1.0, 0.6)
0.0
(−0.5, 0.5)
2001–2011
1.3*
(0.1, 2.5)
6.5
(−5.9, 20.5)
1.3*
(0.0, 2.6)
0.8*
(0.2, 1.5)
0.6 (−1.7, 2.9)
0.2
(−0.8, 1.2)
−1.6 *
(−2.1, 1.0)
−2.3 *
(−3.4, − 1.2)
−2.1*
(−2.7, − 1.5)
2011–2017
1.3*
(0.1, 2.5)
0.3
(−1.6, 2.2)
1.3*
(0.0, 2.6)
4.4* (2.2, 6.7)
3.5* (1.1, 5.9)
3.7*
(1.0, 6.5)
4.1*
(3.1, 5.2)
3.4*
(2.2, 4.6)
3.6*
(2.4, 4.8)
AAPC average annual percent change; CI confidence interval; HF heart failure; KPSC Kaiser Permanente Southern California
Rates of mortality presented as per 100,000 person-years and age-adjusted
*denotes p < 0.05
×
Among members 45–64 years old, between 2001 and 2017 the age-adjusted mortality rate with HF as the underlying cause increased from 1.1 to 2.2 per 100,000 PY in KPSC, representing an AAPC of 1.6% (95% CI − 1.6%, 4.9%). (Additional file 1: Table 1) During this same period, HF mortality rates also increased in California from 2.6 to 4.7 per 100,000 PY (AAPC 3.1%, 95% CI 0.7%, 5.6%) and in the US from 5.2 to 6.4 per 100,000 PY (AAPC 1.6%, 95% CI 1.0%, 2.2%). In KPSC, the AAPCs for women and men 45–64 years old were 2.3% (95% CI − 3.3%, 8.3%) and 1.0% (95% CI − 1.3% to 3.3%), respectively, between 2001 and 2017. Overall and sex-specific HF mortality trends from 2001 to 2017 were not different comparing KPSC to California and the US (all p-values > 0.05 [data not shown]). In KPSC, age-adjusted HF mortality increased at the same rate from 2001 to 2011 and 2011 to 2017. In contrast, HF mortality rates remained flat in CA and in the US from 2001 to 2011 while significantly increasing from 2011 to 2017.
Among members ≥ 65 years old in KPSC, between 2001 and 2017 the age-adjusted mortality rate with HF as the underlying cause of death increased from 64.0 per 100,000 PY in 2001 to 119.4 per 100,000 PY in 2017, representing an AAPC of 1.3% (95% CI 0.0%, 2.5%). (Additional file 1: Table 2) During this same period, HF mortality rates also increased in California from 89.0 to 119.8 per 100,000 PY (AAPC 1.5%, 95% CI 0.2%, 2.8%) but were higher and decreased slightly in the US from 150.6 to 148.4 per 100,000 PY (AAPC − 0.1%, 95% CI − 0.6%, 0.4%). HF mortality trends from 2001 to 2017 were not different comparing KPSC to California; however, mortality trends comparing KPSC to the US were statistically different (p = 0.05 [data not shown]). In KPSC, the AAPCs for women and men ≥ 65 years old were 5.3% (95% CI − 0.3%, 11.3%) and 1.3% (95% CI 0.1%, 2.5%), respectively, between 2001 and 2017. The AAPC among women in KPSC was statistically different from that of the US (5.3% vs − 0.1%, p = 0.05 [data not shown]). No differences were detected comparing KPSC men to California or the US. In KPSC members, age-adjusted HF mortality increased at the same rate from 2001 to 2011 and 2011 to 2017. In contrast, HF mortality rates remained flat in CA and decreased in the US from 2001 to 2011 while significantly increasing in both populations from 2011 to 2017.
Among KPSC enrollees in 2017, API members had the lowest age-adjusted HF mortality (24.8 per 100,000 PY) followed by Hispanic (31.4 per 100,000 PY), white (52.0 per 100,000 PY) and black (53.2 per 100,000 PY) members. (Additional file 1: Table 3) Rates of HF mortality were similar among API but lower among white, Hispanic, and black individuals in KPSC compared to the US. Race/ethnicity-specific variations in HF mortality rates between KPSC, California, and the US were also observed among adults 45–64 years old (Additional file 1: Table 4) and adults ≥ 65 years old (Additional file 1: Table 5).
Table 3
Mortality with HF as a contributing cause in KPSC, California, and the United States, 2001–2017
Year
KPSC
California
United States
Male
Female
Overall
Male
Female
Overall
Male
Female
Overall
2001
188.0
110.7
143.3
232.7
178.7
201.2
232.9
187.2
206.2
2002
190.4
122.6
150.7
233.2
174.9
199.2
228.4
181.2
200.5
2003
183.0
135.1
155.9
231.5
176.0
199.2
223.8
178.3
197.0
2004
192.1
121.7
151.6
220.2
166.9
189.1
215.6
170.5
189.0
2005
198.5
136.7
163.0
220.2
166.2
188.8
214.8
171.3
189.1
2006
188.9
131.6
156.0
211.1
158.7
180.6
203.1
159.5
177.5
2007
179.7
127.8
150.0
193.6
146.6
166.4
192.9
150.6
168.1
2008
175.2
120.0
143.3
192.3
143.4
163.9
188.5
146.6
164.0
2009
181.7
115.0
143.0
184.7
133.7
155.0
182.1
138.1
156.3
2010
175.5
112.1
138.8
181.1
130.9
151.7
181.7
136.3
155.0
2011
172.9
119.6
142.4
178.1
129.8
150.1
176.7
133.3
151.3
2012
164.0
110.6
133.2
173.4
121.4
143.0
176.5
131.0
149.9
2013
171.2
113.5
137.4
176.3
121.2
144.2
181.3
132.9
153.1
2014
162.5
102.7
127.8
167.5
117.2
138.6
183.1
133.5
154.4
2015
163.7
113.6
135.1
177.8
123.8
146.8
190.1
140.2
161.4
2016
166.7
112.0
135.3
182.0
126.2
150.1
191.7
138.3
160.9
2017
170.3
117.0
139.9
183.5
126.6
151.2
194.2
139.3
162.7
AAPC (95% CI)
Overall
−1.0* (−1.4, − 0.7)
0.3 (−1.8, 2.5)
−0.3 (−1.2, 0.6)
−1.7* (−2.3, − 1.2)
−2.1* (−3.1, − 1.1)
−1.7* (−2.7, − 0.8)
−1.2* (−1.5, − 0.9)
−1.9* (−2.3, − 1.5)
−1.5* (−1.9, − 1.2)
2001–2011
− 1.0* (− 1.4, − 0.7)
0.3 (− 2.7, 3.4)
− 0.5 (− 1.6, 0.5)
− 3.1* (− 3.6, − 2.6)
− 3.3* (− 4.5, − 2.1)
− 3.0* (− 4.2, − 1.9)
− 3.0* (− 3.3, − 2.6)
− 3.7* (− 4.1, − 3.2)
− 3.3* (− 3.7, − 3.0)
2011–2017
− 1.0* (− 1.4, − 0.7)
0.4 (− 2.2, 3.0)
0.1 (− 1.3, 1.6)
0.6 (− 0.6, 1.8)
0.1 (− 1.4, 1.6)
0.5 (− 1.0, 1.9)
1.9* (1.2, 2.6)
1.1* (0.1, 2.0)
1.5* (0.8, 2.3)
AAPC average annual percent change; CI confidence interval; HF heart failure; KPSC Kaiser Permanente Southern California
Rates of mortality presented as per 100,000 person-years and age-adjusted
*denotes p < 0.05
HF as a contributing cause of death
Between 2001 and 2017, age-adjusted mortality with HF as a contributing cause followed a similar pattern to mortality with HF as an underlying cause. (Fig. 2) In KPSC, rates changed from 143.3 per 100,000 PY in 2001 to 139.9 per 100,000 PY in 2017, representing an AAPC of − 0.3% (95% CI − 1.2%, 0.6%). (Table 3) During the same time period, rates were higher but also changed in California from 201.2 to 151.2 per 100,000 PY (AAPC − 1.7%, 95% CI − 2.7%, − 0.8%) and in the US from 206.2 to 162.7 per 100,000 PY (AAPC − 1.5%, 95% CI − 1.9%, − 1.2%). Overall trends were different comparing KPSC to California and the US (p-value 0.04 and 0.02, respectively, [data not shown]). In KPSC, from 2001 to 2017 the AAPCs for women and men were 0.3% (95% CI − 1.8%, 2.5%) and − 1.0% (95% CI − 1.4%, − 0.7%), respectively. Trends in KPSC compared to both California and the US were different among women (both p = 0.04) but not for men (p = 0.06 and p = 0.43, respectively, [data not shown]). Between the time periods 2001–2011 and 2011–2017, mortality rates with HF as a contributing cause remained flat in both KPSC and California; in the US, rates decreased from 2001 to 2011 and subsequently increased from 2011 to 2017.
Fig. 2
Mortality with heart failure as a contributing cause in KPSC, California, and the US, 2001–2017
×
Discussion
In the current study, HF mortality rates in KPSC were similar to California but lower than the US, with rates increasing from 2001 to 2017. This was observed in KPSC men but not among women. Trends among KPSC members ≥ 65 years old increased as in the overall population, while no change in HF mortality rates were observed in KPSC members 45–64 years old. Mortality with HF as a contributing cause decreased significantly among KPSC men, but not women. For HF mortality as both an underlying and contributing cause, smaller changes in KPSC compared to California and the US were observed between older (2001–2011) and contemporary (2011–2017) time periods.
HF mortality rates were lower in KPSC compared to the US, and the magnitude of differences in mortality rates between KPSC and the US decreased between 2001 and 2017. Overall, US rates in the current study fluctuated between 48 and 58 per 100,000 PY for all adults ≥ 45 years old, consistent with previous studies. An analysis of data from the National Center for Health Statistics (NCHS) reported 2015 age-adjusted mortality rates with HF as the underlying cause of death ranging from 1.7 per 100,000 PY among US adults 40–49 years old to 441.1 per 100,000 PY among those ≥ 80 years old [27]. While the age compositions of populations in each study may account for the variability of rates, the current study results are similar in magnitude to observed US rates. Reasons for lower HF mortality rates in KPSC, particularly in 2001, may require additional investigation. However, this may be partially attributable to better treatment and management of other preventable causes of death; a previous KPSC study noted that HD mortality decreased between 2001 and 2016 [15]. Lower rates of HF mortality compared to the US may also be attributable to the KPSC integrated healthcare delivery model. KPSC has previously noted improvements in HF risk factors, including blood pressure and lipids [28, 29]. Additionally, while KPSC is representative of the Southern California population, some differences in mortality rates may be explained by the sociodemographic differences between KPSC, California, and the US.
Anzeige
HD mortality, and more specifically, mortality attributable to HF began slowing around 2011, and even increasing more recently [4, 6, 10]. Sidney and colleagues examined US mortality trends attributable to all HD from 2000 to 2015, noting decreasing rates of HF mortality between 2000 and 2011 but annual increases between 2011 and 2015 by 3.73% (95% CI 3.21%, 4.26%) [10] An additional study by Sidney reported this trend continued through 2017, and represented a 38% increase in deaths with HF listed as an underlying cause between 2011 and 2017 [14]. Similar trends were reported using NCHS data, where age-adjusted HF mortality decreased between 2000 and 2012 but increased between 2012 and 2014 [4]. In KPSC, we noted that mortality with HF as an underlying cause increased consistently between 2001 and 2017, which contrasts with the larger AAPCs in California and the US between 2011 and 2017. We did not examine factors contributing to these increases. However, increased awareness of HF as a diagnosis may contribute to the increased designation of HF as the underlying cause of death.
Sex-based differences in HF mortality were noted among adults ≥ 65 years old in KPSC, where women compared with men had a larger AAPC. This is consistent with data from California but differs from that of the US. One explanation could be the higher rates of HF mortality in the US compared to KPSC and California at the beginning of the study period; although it is important to note that an increasing AAPC was noted for HF mortality among older adults from 2011–2017. We also note some differences between KPSC, California, and the US with respect to race/ethnicity. However, we interpret these results cautiously due to small sample sizes within subgroups. Similar to this study, Sidney and colleagues noted differences in annual declines of HF mortality in 2000–2011 and 2011–2015 among sex and race/ethnicity groups [10]. In contrast, an analysis of the National Inpatient Sample between 1991 and 2015 reported HF mortality rates varied by race/ethnicity but not sex [27].
Previous studies using national data have reported declines in mortality with HF as a contributing cause. Glynn and colleagues reported a decline through 2011–2012, but an increase through 2012–2017, while a separate study reported a decline through 2014 [4, 23]. Reasons why declines in HF mortality are observed through 2011 may include the emphasis of blood pressure and cholesterol management, and increased smoking cessation. Sustained increases in comorbidities such as obesity and diabetes, reduced mortality from other forms of CVD, and the growth of the population ≥ 65 years old may explain more recent increases in HF mortality [10, 14, 15, 30, 31]. Emphasis on treating and managing HF and accompanying risk factors may help reduce these increasing rates of mortality.
We acknowledge some limitations. HF is considered a mediator between various disease states and mortality, and HF listed as an underlying cause of death may be attributable to other conditions [1]. Thus, ICD-10 coding guidelines suggest listing other plausible heart conditions as the underlying cause of death and listing HF when the etiology cannot be determined. Regardless, we observed similar patterns in mortality with HF listed as a contributing cause of death. Additionally, deaths among KPSC enrollees occurring outside of California may not be completely captured. After 2011, a law was established that prevented the SSA from disclosing state death records received through its contracts. However, it was assumed that most deaths outside of the state of California were reported to KPSC by family, employers, caregivers, doctors outside of the state, and law enforcement. Additionally, cause of death was not available on all enrollees, which may underestimate HF-specific mortality. In the current study, we noted small numbers of HF mortality among stratified subgroups by younger age (45–64 years) and race/ethnicity, which limits the interpretability of our findings. Rates of mortality in the KPSC population may not be generalizable to uninsured populations. Additionally, race/ethnicity was not available for all members. Finally, factors associated with HF mortality were not examined, and this warrants further investigation. Prior work has shown that patient self-care (e.g., weight monitoring, medication adherence, healthy lifestyle behaviors, and comorbidity management) and other care-related factors (e.g., patient education and connection with care) are important in the prognosis of HF patients. [32‐34]
Anzeige
In conclusion, lower rates of HF mortality were observed in KPSC compared to the US. Given the aging of the US population and increasing prevalence of HF, it will be important to examine individual and care-related factors driving susceptibility to HF mortality.
Acknowledgements
Parts of this study were presented as an abstract at the American Heart Association Quality of Care and Outcomes Research virtual conference, May 15-16, 2020. The abstract was published online: Mefford, M., Zhuang, Z., Liang, Z., Chen, W., Watson, H., Koyama, S.Y., Lee, M., Sidney, S., & Reynolds, K. (2020). Abstract 270: Temporal Trends in Heart Failure Mortality in an Integrated Healthcare Delivery System, California and the US, 2001-2017. Circulation: Cardiovascular Quality and Outcomes, 13.
Declarations
Ethics approval and consent to participate
The study protocol was approved by the KPSC institutional review board. A waiver of consent was approved due to the minimal risk of the study.
Consent for publication
Not applicable.
Anzeige
Competing interests
The authors declare no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
